20 results about "Dutasteride" patented technology

There is provided a pharmaceutical composition comprising, as active ingredients: 5 mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution rate of tadalafil is 60-75% after 5 minutes and 80% or more after 30 minutes under dissolution conditions of a paddle speed of 50 rpm in 500 mL of a dissolution solution having a pH of 1.2 and containing 0.25% of SLS, and the dissolution rate of dutasteride is 50% or more after 15 minutes and 85% or more after 30 minutes under dissolution conditions of a paddle speed of 50 rpm in 500 mL of a dissolution solution containing water and 0.1% of SLS.

The invention relates to a compound as shown in a formula (I) or a salt or a solvate thereof, and also relates to a preparation method of the compound as shown in the formula (I), a pharmaceutical composition containing the compound as shown in the formula (I), and application of the compound as shown in the formula (I) or the pharmaceutical composition containing the compound as shown in the formula (I) in preparation of medicines for treating alopecia and benign prostatic hyperplasia. Through injection administration, the administration effect can be maintained for a long time, and the long-acting pharmaceutical property is ideal.

Provided is a pharmaceutical composition comprising as active ingredients: 5 mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution rate of tadalafil under the dissolution conditions of a paddle rate of 50 rpm in 500 mL of a dissolution solution having a pH of 1.2 and containing 0.25% of SLS is 60-75% after 5 minutes and 80% or more after 30 minutes, and the dissolution rate of dutasteride under the dissolution conditions of a paddle rate of 50 rpm in 500 mL of a dissolution solution containing water and 0.1% of SLS is 50% or more after 15 minutes and 85% or more after 30 minutes.

The application discloses a 4-azasteroid compound, wherein the C-10 position methyl is in alpha configuration, and the 4-azasteroid compound has strong inhibiting effect on prostate cancer and colon cancer cells in addition to the drug activity of finasteride / dutasteride. The preparation method of the 4-azasteroid compound is simple in operation, high in efficiency, low in cost, environment-friendly, high in product purity, free of toxic by-products, and high in yield, and is suitable for large-scale industrial production. The application further discloses the use of the 4-azasteroid compound in the preparation of a drug for inhibiting cancer cells, and a pharmaceutical composition composed of the 4-azasteroid compound, which is verified by pharmacological experiments to have strong inhibiting effect on prostate cancer and colon cancer cells, and has a good application prospect in the preparation of the drug for inhibiting cancer cells.

The invention relates to the technical field of pharmaceutical preparations. The invention provides a sustained-release capsule containing minoxidil and dutasteride and a preparation method of the sustained-release capsule, the sustained-release capsule is composed of a capsule shell and content, and the content comprises minoxidil, dutasteride, spirolactone, isovitamin A, a traditional Chinese medicine composition, a sustained-release material, a filling material, an adhesive, a lubricant, a traditional Chinese medicine solubilizing dispersant and a stabilizer. According to the sustained-release capsule, through the synergistic effect of chemical components and traditional Chinese medicine components, the medicine components are better and more stable, the duration time of the medicine effect is prolonged, and the side effects of hirsutism, edema and the like caused by minoxidil and the side effects of transaminase abnormality and the like caused by dutasteride are reduced; meanwhile, by means of the liver protecting and blood nourishing effects of the traditional Chinese medicine components, the liver metabolism pressure is better reduced, and the long-term medication safety is improved; the hair regeneration capability is enhanced, and a better alopecia prevention and treatment effect is achieved.

A method for promoting hair regrowth in a subject includes performing microneedling on a region of a scalp of the subject to a depth of 0.5 millimeters (mm) to 1.5 mm, applying at least one therapeutic agent to the microneedled region, wherein the at least one therapeutic agent comprises Minoxidil, Finasteride, and Dutasteride, and implanting non-permanent pigment particles into a superficial dermis of the microneedled region, the microneedling, the applying, and the implanting together synergistically stimulating hair follicle activity.

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis, the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

An embodiment relates to a sustained-release injectable composition containing dutasteride, which may exhibit a sustained dutasteride release effect for 3 months or more even when the dose of dutasteride is equal to or less than that of existing AVODART®, which is taken once a day, thereby exhibiting a long-acting drug effect by a single injection. In addition, the injectable composition may exhibit a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more, may maintain an effective concentration of the drug at a constant level by controlling the release of the drug due to the constant average diameter of the microparticles contained in the sustained-release injectable composition, and may reduce foreign body sensation and pain when administered by injection to a patient.

The present invention relates to a sustained-release injectable composition containing dutasteride, which may exhibit a sustained dutasteride release effect for 3 months or more even when the dose of dutasteride is equal to or less than that of existing AVODART®, which is taken once a day, thereby exhibiting a long-acting drug effect by a single injection. In addition, the injectable composition may exhibit a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more, may maintain an effective concentration of the drug at a constant level by controlling the release of the drug due to the constant average diameter of the microparticles contained in the sustained-release injectable composition, and may reduce foreign body sensation and pain when administered by injection to a patient.

In one aspect, the disclosure relates to topical formulations, methods of making same, and methods of treating hair loss using same. In an aspect, the present disclosure pertains to topical formulations for treatment of hair loss and / or to increase hair growth, the formulation comprising: a therapeutic composition comprising therapeutically effective amounts of azelaic acid, minoxidil, finasteride, and dutasteride; and one or more compounding agents. In a further aspect, the present disclosure pertains to a method of treating hair loss by applying a disclosed topical formulation. In a further aspect, the present disclosure pertains to a method of enhancing hair grow by applying a disclosed topical formulation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The application belongs to the technical field of chemical pharmacy, and particularly relates to a method for preparing dutasteride crystal form I. The method specifically comprises the following steps: S1, dissolving crude dutasteride in methanol; S2, adding small-molecule saturated alkane, and distilling under stirring until no methanol is distilled out; S3, cooling and standing the mixture to precipitate crystals; and S4, filtering, and drying the filter cake to obtain dutasteride crystal form I. The method uses a methanol-small-molecule saturated alkane double-solvent distillation recrystallization method, and dutasteride crystal form I can be obtained through simple dissolving, distilling, filtering and drying operations. The method overcomes the problems in the prior art, such as difficult control of the reaction process, easy occurrence of mixed crystals, poor repeatability, excessive solvent residue and the like, has the characteristics of simple controllability, high crystal purity, good repeatability and low solvent residue, is suitable for large-scale production, and has a good industrial application prospect.

The invention discloses a novel synthesis method of dutasteride, which is characterized in that sodium perborate is used as an oxidizing agent, and a proper solvent system and pH value are designed, so that efficient oxidation of hydrogenated dutasteride carboxylic acid iodide is realized, toxic reagents are prevented from being used, and impurities can be reduced; the high-purity dutasteride can be obtained through simple refining, the operability is high, and the method is suitable for industrial mass production.

A method for the treatment or prevention of the symptoms or effects of hair loss of an animal which comprises treating the animal with a therapeutically effective amount of a combination comprising 7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone or a physiologically functional derivative thereof, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide or a physiologically functional derivative thereof, 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one or a physiologically functional derivative thereof, and 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide or a physiologically functional derivative thereof. A pharmaceutical formulation comprising the same. A patient pack comprising at least one active ingredient selected from 7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone or a physiologically functional derivative thereof, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, and 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide, and an information insert containing directions on the use of all three active ingredients together in combination.

A composition of the present invention relates to a composition comprising dutasteride, wherein said composition may maintain a constant concentration of dutasteride in blood and continuously release a drug thereof for a long period of time while not precipitating dutasteride in a solid form when being administered into the human body, and also has an excellent safety without causing local irritations in an administration site.

The present invention relates to a composition for alleviating or treating hair loss in which a hair loss drug is loaded in lipid nanoparticles. The lipid nanoparticles contain 0.30 mol% or more of a hydrophobic drug such as finasteride or dutasteride relative to the lipid nanoparticles and are loaded with the hydrophobic drug at an encapsulation rate of 90.0% or more, and thus have the advantage of being able to maintain water dispersibility for a long period of time while increasing transdermal delivery. Therefore, the present invention can more effectively alleviate symptoms of male pattern hair loss on the scalp where localized hair loss or thinning of hair occurs.

Topical compositions and kits are provided for hair regrowth, hair loss prevention, and scalp health improvement. These formulations contain at least one active (e.g., finasteride, minoxidil, dutasteride, and latanoprost), at least one penetration enhancer (e.g., Transcutol®, laurocapram), stabilizers, and anti-inflammatory agents like retinoic acid, hydrocortisone, and aloe vera. They utilize optimized particle sizes (D90 ≤8.5 μm, span ≤1.7) and may include bioadhesive polymers or nanoparticles for enhanced follicular delivery and extended residence. Modular kits offer multi-chambered packaging, calibrated droppers, and app- or sensor-guided dispensing for customizable ingredient mixing and regimen personalization. These innovations improve active stability, minimize irritation, and yield superior clinical outcomes (hair density and quality) over traditional therapies. Methods include treating varied alopecia types, with or without device-assisted delivery (microneedling, light therapy), alongside digital monitoring, compliance tracking, and optional diagnostic or conditioning tools for individualized scalp and hair care.

The present invention relates to the use of combination of 5α-reductase inhibitors and prostaglandin analogues for preventing hair loss and / or stimulating hair growth. The present invention also relates to topical composition containing 5α-reductase inhibitors and prostaglandin analogues for preventing hair loss and / or stimulating hair growth on the scalp. The present invention also relates to composition and methods for treating certain hair loss disorders such as androgenetic alopecia.

The invention relates to a composition comprising minoxidil and dutasteride with one or more pharmaceutically acceptable excipient. Further the invention relates to process of preparing such composition. Further the invention relates to topical application of the composition for preventing hair loss and / or stimulating hair growth. Further invention relates to achieving acceptable pharmacokinetic parameters to give beneficial therapeutic effect with minimal side effects.Fig. 1A

The present application provides a kind of local pharmaceutical composition comprising 5 alpha-reductase inhibitor, penetration agent, hydroxypropyl methyl cellulose and water, and the 5 alpha-reductase inhibitor is finasteride or dutasteride.The composition of the present application has good spraying effect, stable in-vitro skin retention, and shows good hair growth effect on mouse androgenetic alopecia model, and the hair growth effect is better than that of prior art, and the skin feel is better, and is not sticky.

This invention provides a dutasteride nanosuspension. It also provides soluble microneedles loaded with the dutasteride nanosuspension. The DUT nanosuspension is prepared using an antisolvent method combined with high-pressure homogenization to improve solubility and stability. Combined with microneedle drug delivery technology, the dutasteride nanosuspension is loaded onto soluble microneedles for topical skin administration, reducing the systemic side effects that may result from long-term oral DUT. Simultaneously, it increases the drug concentration of DUT in the skin layer, especially in hair follicles, thereby enhancing drug efficacy. Furthermore, the microneedles create microporous channels in the stratum corneum and epidermis, facilitating the smooth penetration of dutasteride through the stratum corneum, increasing its transdermal permeability, and improving transdermal absorption. This provides a research foundation for the clinical application and further development of dutasteride transdermal drug delivery for the treatment of androgenetic alopecia.